{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T08:23:09Z","timestamp":1763194989049,"version":"3.45.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06580-y","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T01:29:48Z","timestamp":1759109388000},"page":"5237-5256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epidemiology of chronic lymphocytic leukaemia in Germany: A retrospective analysis of administrative claims data"],"prefix":"10.1007","volume":"104","author":[{"given":"Phillen Nozibuyiso","family":"Maqhuzu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derya","family":"Bocuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Boelz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina Khageh","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Leeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Renevey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Mevius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Greth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Christofyllakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"4","key":"6580_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3238\/arztebl.2019.0041","volume":"116","author":"JV Tresckow","year":"2019","unstructured":"Tresckow JV, Eichhorst B, Bahlo J, Hallek M (2019) The treatment of chronic lymphatic leukemia. Dtsch Arztebl Int 116(4):41\u201346. https:\/\/doi.org\/10.3238\/arztebl.2019.0041","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"6580_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"6580_CR3","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1080\/14656566.2024.2398603","volume":"25","author":"IJ Huang","year":"2024","unstructured":"Huang IJ, Baek GT, Siu C, Shadman M (2024) Pharmacological management of chronic lymphocytic leukemia: current and emerging therapies. Expert Opin Pharmacother 25(13):1759\u20131783. https:\/\/doi.org\/10.1080\/14656566.2024.2398603","journal-title":"Expert Opin Pharmacother"},{"key":"6580_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27546","author":"M Hallek","year":"2025","unstructured":"Hallek M (2025) Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.27546","journal-title":"Am J Hematol"},{"key":"6580_CR5","doi-asserted-by":"publisher","unstructured":"Eichhorst B, Ghia P, Niemann CU, Kater AP, Gregor M, Hallek M, Jerkeman M, Buske C clinicalguidelines@esmo.org EGCEa (2024) ESMO clinical practice guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol 35 (9):762\u2013768. https:\/\/doi.org\/10.1016\/j.annonc.2024.06.016","DOI":"10.1016\/j.annonc.2024.06.016"},{"key":"6580_CR6","unstructured":"Leitlinienprogramm O (2024) S3-Leitlinie Diagnostik, Therapie und Nachsorge f\u00fcr Patient innen mit einer chronischen lymphati-schen Leuk\u00e4mie (CLL) (version 2.0 \u2013 December 2024). Available at https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/chronische-lymphatische-leukaemie-cll. Accessed"},{"issue":"16","key":"6580_CR7","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","volume":"21","author":"RA de Claro","year":"2015","unstructured":"de Claro RA, McGinn KM, Verdun N, Lee SL, Chiu HJ, Saber H, Brower ME, Chang CJ, Pfuma E, Habtemariam B, Bullock J, Wang Y, Nie L, Chen XH, Lu DR, Al-Hakim A, Kane RC, Kaminskas E, Justice R, Farrell AT, Pazdur R (2015) FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clin Cancer Res 21(16):3586\u20133590. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2225","journal-title":"Clin Cancer Res"},{"issue":"11","key":"6580_CR8","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2023.1946","volume":"329","author":"M Shadman","year":"2023","unstructured":"Shadman M (2023) Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA 329(11):918\u2013932. https:\/\/doi.org\/10.1001\/jama.2023.1946","journal-title":"JAMA"},{"key":"6580_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.20517\/cdr.2023.100","volume":"7","author":"A Borogovac","year":"2024","unstructured":"Borogovac A, Siddiqi T (2024) Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them. Cancer Drug Resist 7:18. https:\/\/doi.org\/10.20517\/cdr.2023.100","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"6580_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41408-024-01001-1","volume":"14","author":"R Bennett","year":"2024","unstructured":"Bennett R, Seymour JF (2024) Update on the management of relapsed\/refractory chronic lymphocytic leukemia. Blood Cancer J 14(1):33. https:\/\/doi.org\/10.1038\/s41408-024-01001-1","journal-title":"Blood Cancer J"},{"key":"6580_CR11","doi-asserted-by":"publisher","first-page":"12302","DOI":"10.3389\/jpps.2024.12302","volume":"27","author":"K Zisis","year":"2024","unstructured":"Zisis K, Pavi E, Geitona M, Athanasakis K (2024) Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process. J Pharm Pharm Sci 27:12302. https:\/\/doi.org\/10.3389\/jpps.2024.12302","journal-title":"J Pharm Pharm Sci"},{"issue":"1","key":"6580_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/cpt.2449","volume":"111","author":"D McNair","year":"2022","unstructured":"McNair D, Lumpkin M, Kern S, Hartman D (2022) Use of RWE to inform regulatory, public health policy, and intervention priorities for the developing world. Clin Pharmacol Ther 111(1):44\u201351. https:\/\/doi.org\/10.1002\/cpt.2449","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"6580_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12874-022-01768-6","volume":"22","author":"F Liu","year":"2022","unstructured":"Liu F, Panagiotakos D (2022) Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Med Res Methodol 22(1):287. https:\/\/doi.org\/10.1186\/s12874-022-01768-6","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"6580_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/pds.1721","volume":"18","author":"F Hoffmann","year":"2009","unstructured":"Hoffmann F (2009) Review on use of German health insurance medication claims data for epidemiological research. Pharmacoepidemiol Drug Saf 18(5):349\u2013356. https:\/\/doi.org\/10.1002\/pds.1721","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"6580_CR15","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10198-016-0849-3","volume":"18","author":"S Neubauer","year":"2017","unstructured":"Neubauer S, Kreis K, Klora M, Zeidler J (2017) Access, use, and challenges of claims data analyses in Germany. Eur J Health Econ 18(5):533\u2013536. https:\/\/doi.org\/10.1007\/s10198-016-0849-3","journal-title":"Eur J Health Econ"},{"issue":"2","key":"6580_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.healthpol.2016.01.007","volume":"120","author":"K Kreis","year":"2016","unstructured":"Kreis K, Neubauer S, Klora M, Lange A, Zeidler J (2016) Status and perspectives of claims data analyses in Germany-A systematic review. Health Policy 120(2):213\u2013226. https:\/\/doi.org\/10.1016\/j.healthpol.2016.01.007","journal-title":"Health Policy"},{"issue":"2","key":"6580_CR17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/jha2.888","volume":"5","author":"H Wartmann","year":"2024","unstructured":"Wartmann H, Kabilka A, Deiters B, Schmitz N, Volmer T (2024) A decade of chronic lymphocytic leukaemia therapy in Germany: Real-world treatment patterns and outcomes (2010\u20132022). EJHaem 5(2):346\u2013352. https:\/\/doi.org\/10.1002\/jha2.888","journal-title":"EJHaem"},{"key":"6580_CR18","unstructured":"Gesetzliche K (2024) Mitglieder, itversicherte Angeh\u00f6rige und Krankenstand Monatswerte. Januar - Dezember 2024. Available at https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/3_Downloads\/Statistiken\/GKV\/Mitglieder_Versicherte\/KM1_Januar_bis_Dezember_2024.pdf. Accessed 6 February 2025"},{"key":"6580_CR19","unstructured":"Deutschland.de (2024) Who pays in the event of sickness? Available at https:\/\/www.deutschland.de\/en\/topic\/life\/health-in-germany-how-health-insurance-companies-work. Accessed 6 February 2025"},{"issue":"10097","key":"6580_CR20","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0140-6736(17)31280-1","volume":"390","author":"R Busse","year":"2017","unstructured":"Busse R, Blumel M, Knieps F, Barnighausen T (2017) Statutory health insurance in germany: a health system shaped by 135 years of solidarity, self-governance, and competition. Lancet 390(10097):882\u2013897. https:\/\/doi.org\/10.1016\/S0140-6736(17)31280-1","journal-title":"Lancet"},{"issue":"6","key":"6580_CR21","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00277-016-2640-z","volume":"95","author":"AK Zoellner","year":"2016","unstructured":"Zoellner AK, Hohler T, Fries S, Bohme A, Kiewe P, Kellermann L, Dreyling M (2016) Altered treatment of chronic lymphocytic leukemia in Germany during the last decade. Ann Hematol 95(6):853\u2013861. https:\/\/doi.org\/10.1007\/s00277-016-2640-z","journal-title":"Ann Hematol"},{"key":"6580_CR22","doi-asserted-by":"publisher","unstructured":"Horenkamp-Sonntag D, Linder R, Wenzel F, Gerste G, Ihle P (2014) Pr\u00fcfung der Datenqualit\u00e4t und Validit\u00e4t von GKV-Routinedaten. In: Swart E, Ihle P, Gothe H, Matusiewicz D (eds) Routinedaten im Gesundheitswesen. Handbuch Sekund\u00e4rdatenanalyse: Grundlagen, Methoden und Perspektiven, vol First edition. Verlag Hans Huber, Hogrefe AG, Bern, pp 314\u2013330. https:\/\/doi.org\/10.1055\/s-0035-1548786","DOI":"10.1055\/s-0035-1548786"},{"issue":"3","key":"6580_CR23","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1093\/oncolo\/oyad324","volume":"29","author":"X Yang","year":"2024","unstructured":"Yang X, Zanardo E, Lejeune D, De Nigris E, Sarpong E, Farooqui M, Laliberte F (2024) Treatment patterns, healthcare resource utilization, and costs of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in the US. Oncologist 29(3):e360\u2013e371. https:\/\/doi.org\/10.1093\/oncolo\/oyad324","journal-title":"Oncologist"},{"key":"6580_CR24","unstructured":"Wendtner C-M, Al-Sawaf O, Binder M, Dreger P, Eichhorst B, Gregor M, Greil R, Hallek M, Holtkamp U, Knauf WU, Pritzkuleit R, Schetelig J, Schwaner I, Staber PB, W\u00f6rmann B, Zenz T, Stilgenbauer S (2024) Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Medizinische Onkologie e.V. (DGHO), Chronische Lymphatische Leuk\u00e4mie (CLL)\u2014Leitlinie 2024. Available at https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/chronische-lymphatische-leukaemie-cll\/@@guideline\/html\/index.html. Accessed 4 February 2025"},{"key":"6580_CR25","doi-asserted-by":"publisher","first-page":"840616","DOI":"10.3389\/fonc.2022.840616","volume":"12","author":"Y Ou","year":"2022","unstructured":"Ou Y, Long Y, Ji L, Zhan Y, Qiao T, Wang X, Chen H, Cheng Y (2022) Trends in disease burden of chronic lymphocytic leukemia at the global, regional, and National levels from 1990 to 2019, and projections until 2030: a population-based epidemiologic study. Front Oncol 12:840616. https:\/\/doi.org\/10.3389\/fonc.2022.840616","journal-title":"Front Oncol"},{"issue":"16suppl","key":"6580_CR26","doi-asserted-by":"publisher","first-page":"e19020","DOI":"10.1200\/JCO.2024.42.16_suppl.e19020","volume":"42","author":"J-Z Hou","year":"2024","unstructured":"Hou J-Z, Blanc S, Maglinte GA, Vasudevan A, Rui A, Gart M, Pham H, Aton L, Wang B, Choksi RJ (2024) Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL) in US community oncology practices. J Clin Oncol 42(16suppl):e19020\u2013e19020. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e19020","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"6580_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1182\/blood-2023-174289","volume":"142","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst BF, Lamanna N, O\u2019Brien SM, Tam CS, Qiu L, Ka\u017amierczak M, Jurczak W, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy AL, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Wang M, Salmi T, Wang L, Li J, Wu K, Cohen AC, Shadman M (2023) Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R\/R CLL\/SLL). Blood 142(Supplement 1):202\u2013202. https:\/\/doi.org\/10.1182\/blood-2023-174289","journal-title":"Blood"},{"issue":"16","key":"6580_CR28","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1182\/bloodadvances.2023009739","volume":"7","author":"LE Roeker","year":"2023","unstructured":"Roeker LE, DerSarkissian M, Ryan K, Chen Y, Duh MS, Wahlstrom SK, Hakre S, Yu L, Guo H, Mato AR (2023) Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia. Blood Adv 7(16):4291\u20134301. https:\/\/doi.org\/10.1182\/bloodadvances.2023009739","journal-title":"Blood Adv"},{"key":"6580_CR29","unstructured":"AstraZeneca AB (2020) (Nov CALQUENCE\u00ae (acalabrutinib) capsules, for oral use. Summary of Product Characteristics. European Medicines Agency. Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/calquence-epar-product-information_en.pdf"},{"key":"6580_CR30","unstructured":"BeiGene Ireland L (2021) (Nov BRUKINSA\u00ae (zanubrutinib) capsules, for oral use. Summary of Product Characteristics. European Medicines Agency. Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/brukinsa-epar-product-information_en.pdf"},{"issue":"11","key":"6580_CR31","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1080\/10428194.2024.2374040","volume":"65","author":"C Tam","year":"2024","unstructured":"Tam C, Zhao FL, Azam S, Li SC, Tang B (2024) Real-world treatment patterns and outcomes for patients with CLL using the Australian pharmaceutical benefits scheme (PBS) dataset. Leuk Lymphoma 65(11):1576\u20131585. https:\/\/doi.org\/10.1080\/10428194.2024.2374040","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"6580_CR32","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1080\/10428194.2023.2232489","volume":"64","author":"M Arguello-Tomas","year":"2023","unstructured":"Arguello-Tomas M, Albiol N, Jara P, Garcia-Cadenas I, Redondo S, Esquirol A, Novelli S, Saavedra S, Martino R, Nomdedeu J, Sierra J, Mora A, Moreno C (2023) Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: experience from one European center. Leuk Lymphoma 64(10):1655\u20131661. https:\/\/doi.org\/10.1080\/10428194.2023.2232489","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"6580_CR33","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1\/198::aid-cncr2820480131\/3.0.co;2-v","volume":"48","author":"JL Binet","year":"1981","unstructured":"Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, Gremy F (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48(1):198\u2013206. https:\/\/doi.org\/10.1002\/1097-0142(19810701)48:1\/198::aid-cncr2820480131\/3.0.co;2-v","journal-title":"Cancer"},{"key":"6580_CR34","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/hematology.2020000118","volume":"2020 1","author":"A Lipsky","year":"2020","unstructured":"Lipsky A, Lamanna N (2020) Managing toxicities of Bruton tyrosine kinase inhibitors. Hematol Am Soc Hematol Educ Program 2020 1:336\u2013345. https:\/\/doi.org\/10.1182\/hematology.2020000118","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"4","key":"6580_CR35","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.hoc.2021.03.008","volume":"35","author":"MC Thompson","year":"2021","unstructured":"Thompson MC, Mato AR (2021) Treatment of chronic lymphocytic leukemia after discontinuation of bruton\u2019s tyrosine kinase inhibitors. Hematol Oncol Clin North Am 35(4):793\u2013806. https:\/\/doi.org\/10.1016\/j.hoc.2021.03.008","journal-title":"Hematol Oncol Clin North Am"},{"issue":"10","key":"6580_CR36","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.3390\/cancers13102468","volume":"13","author":"M Bewarder","year":"2021","unstructured":"Bewarder M, Stilgenbauer S, Thurner L, Kaddu-Mulindwa D (2021) Current treatment options in CLL. Cancers (Basel) 13(10):2468. https:\/\/doi.org\/10.3390\/cancers13102468","journal-title":"Cancers (Basel)"},{"issue":"3","key":"6580_CR37","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/10428194.2019.1680840","volume":"61","author":"R Weide","year":"2020","unstructured":"Weide R, Feiten S, Chakupurakal G, Friesenhahn V, Kleboth K, Koppler H, Lutschkin J, van Roye C, Thomalla J, Heymanns J (2020) Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care\u00a01995-2017. Leuk Lymphoma 61(3):557\u2013566. https:\/\/doi.org\/10.1080\/10428194.2019.1680840","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"6580_CR38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10552-018-1004-5","volume":"29","author":"M Solans","year":"2018","unstructured":"Solans M, Osca-Gelis G, Comas R, Roncero JM, Gallardo D, Marcos-Gragera R, Saez M (2018) Challenges in assessing the real incidence of chronic lymphocytic leukemia: 16 years of epidemiological data from the province of Girona, Spain. Cancer Causes Control 29(3):379\u2013382. https:\/\/doi.org\/10.1007\/s10552-018-1004-5","journal-title":"Cancer Causes Control"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06580-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06580-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06580-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T08:19:16Z","timestamp":1763194756000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06580-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6580"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06580-y","relation":{},"ISSN":["1432-0584"],"issn-type":[{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was not required since it was based on anonymised claims data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"PM, DB, SB, SH, CL and FR are employees of Eli Lilly. DB is a minor shareholder of Eli Lilly. AM and KG declare no competing interests. KC has received educational and\/or travel grants and\/or research funding from AbbVie, AstraZeneca, Beigene, Celgene, Grifols, Jazz Pharmaceuticals, Hexal, Lilly and Novartis. KC has received honoraria from AstraZeneca, Takeda and Roche. KC has participated in advisory boards and\/or speaker bureaus for AstraZeneca, Beigene, BMS, Janssen, Kite\/Gilead, Novartis, Takeda and Sobi.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}